Clinical trials: Experimental Group
Triple Negative Breast Cancer
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic…
- Trial name
- NCT07879911
- Testing
- Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）
- Volunteers
- 550 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Influenza
Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in adults aged 18 to 60 years.
- Trial name
- NCT00989287
- Testing
- GSK2340272A, GSK2340269A
- Where
- Belgium
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Castration-resistant Prostate Cancer
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
- Trial name
- NCT03692663
- Testing
- TABP EIC, Cyclophosphamide, fludarabine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Healthy Volunteers
Phase I Study of GST-HG151 Tablets in Healthy Volunteers
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Impact of GST-HG151 Tablets in Single-dose and Multiple-dose in Healthy Volunteers
- Trial name
- NCT05345964
- Testing
- GST-HG151
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
Wound Healing
Evaluating the Efficacy and Safety of the VERAFLO™ Dressing Kit for Wound Bed Preparation in Open Wounds
The objectives are to evaluate the efficacy and safety of the V.A.C. VERAFLO™ Dressing Kit for wound bed preparation in open wounds with extensive soft tissue damage in this trial.
- Trial name
- NCT05902793
- Testing
- Investigational device: V.A.C. VERAFLO™ Dressing Kit, Comparator device: Negative pressure wound drainage material
- Where
- 4 sites in China
- Volunteers
- 170 people
- Sponsor
- KCI USA, Inc
Leg Ulcers, Leg Ulcers Venous
Vacuum Compression Therapy and Tissue Oxygenation in Chronic Leg Ulcers
Chronic lower limb ulcers, particularly those of venous etiology, are difficult-to-heal wounds that severely affect patients' quality of life. Adequate tissue oxygenation is essential for wound healing.
- Trial name
- NCT07901517
- Testing
- Vacuum Compression Therapy (VCT), Standard Wound Care
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- BTL Industries Ltd.
Chronic Kidney Diseases, Kidney Injury, Acute
Clinical Performance of a Point-of-Care Creatinine Testing System in Individuals With Kidney Disease
The goal of this clinical performance study is to evaluate the accuracy and usability of the Eaglenos Creatinine Test System（referred to as EG）, a point-of-care testing (POCT) system that consists of a handheld device and its…
- Trial name
- NCT07251075
- Testing
- Reference Creatinine Test System（Cobas c 111）, Investigational Creatinine Test System （EG）
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tingting Xu
Epidemic Influenza
Phase IIaTrials of GanMaoKangNing Granules
Randomized, double-blind, double- simulation, positive drug-and-Placebo-Controlled, multicenter, phase IIa clinical trials Study about GanMaoKangNing Granules in improving the symptoms of influenza.
- Trial name
- NCT02989012
- Testing
- GanMaoKangNing Granules, Analogous Oseltamivir Phosphate Capsules, Oseltamivir Phosphate Capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Dalian Zhen-Ao Bio-Tech Co., Ltd.
Brain Diseases, Vertebral Artery Thrombosis
A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX
Aprospective, multicentre, single-arm clinical trial in which approximately 36 subjects would be enrolled using the Bridge 4.5 mm and 5.0 mm stent in accordance with the inclusion and exclusion criteria in this protocol.
- Conditions
- Brain Diseases, Vertebral Artery Thrombosis, Vertebral Artery Stenosis
- Trial name
- NCT06186024
- Testing
- Bridge
- Where
- China
- Volunteers
- 36 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Knee Injuries, Cartilage Injury
Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee
Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the knee with microfracture plus the Chondro-Gide® ACC is non-inferior to treatment…
- Conditions
- Knee Injuries, Cartilage Injury, Cartilage Disease, Knee Discomfort
- Trial name
- SECURE (NCT04537013)
- Testing
- Microfracture, Microfracture plus placement of Chondro-Gide® ACC
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 82 people
- Sponsor
- Geistlich Pharma AG
Primary Hyperlipidemia
Zhibitai Capsules for the Treatment of Primary Hyperlipidemia
Exploring the benefit risk ratio of increase in dosage of Zhibitai capsules (2 capsules at a time, 2 times a day) compared to the original dosage (1 capsule at a time, 1 day)
- Trial name
- NCT06822946
- Testing
- zhibitai capsule
- Where
- 12 sites in China
- Volunteers
- 201 people
- Sponsor
- Chengdu Diao Jiuhong Pharmaceutical Factory
Chronic Pain
A Single Arm, Open-label First In Human Study for Assessing the Safety and Performance of the EpiFinder in Subjects With Clinical Indication for Lumbar Epidural Steroids Injection (ESI)
The EpiFinder device, which is the investigational device in this study, is intended for use in epidural procedures, between a luer syringe and an epidural needle, to give the treating physician a clear indication that the needle…
- Trial name
- NCT04047927
- Testing
- EpiFinder
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Omeq Medical
Growth and Tolerance
Growth and Tolerance of Young Infants Fed Infant Formula
This is a randomized, multicenter, controlled, double-blind, parallel study to evaluate growth and tolerance of healthy term infants fed milk-based infant formulas.
- Trial name
- NCT04105686
- Testing
- Control Infant Formula, Experimental Infant Formula
- Where
- 32 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Depressive Disorder and Anxiety Disorders
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
This will be a phase I, single centre, randomised, double blind, double-dummy, placebo controlled, parallel group single-dose study in healthy volunteers.
- Trial name
- NCT01424384
- Testing
- Citalopram, GSK424887, Plactebo To Match
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Urinary Retention
A Confirmatory Study Confirming Performance of a New Intermittent Catheter
A multi-centre, randomized, controlled crossover design. The total study duration for the individual subject was approximately 9 weeks.
- Trial name
- NCT05485935
- Testing
- Investigational device - intermittent catheter with micro-hole zone, Comparator - standard intermittent catheter
- Where
- 6 sites in Denmark, France and 2 more
- Volunteers
- 73 people
- Sponsor
- Coloplast A/S
Patients With Bacterial Vaginosis
Effects of Lacticaseibacillus Rhamnosus LRa05 on Bacterial Vaginosis and Ovarian Function in Women
In this study, Lacticaseibacillus rhamnosus LRa05 was selected as test preparations to observe the clinical efficacy in the intervention trial of combined antibiotic therapy, and to evaluate its effects on the cure rate…
- Trial name
- NCT06821789
- Testing
- Probiotic
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Hemophilia A
A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A
The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-010 in subjects with hemophilia A.
- Trial name
- EDELWEISS (NCT06185335)
- Testing
- ANB-010, dose 1, ANB-010, dose 2, ANB-010, dose 3
- Where
- 17 sites in Russia
- Volunteers
- 50 people
- Sponsor
- Biocad
Healthy Volunteers
Aom0319 SAD Study in Healthy Subjects
Only SAD study will be conducted in this project. SAD represents single ascending dose. Multiple ascending dose have been cancelled. This decision has been made at the discretion of the Sponsor.
- Trial name
- NCT05555758
- Testing
- Adamgammadex Sodium, 0.9% Sodium Chloride Injection
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Amckaus PTY LTD.
Upper Extremity Paresis, Stroke, Chronic
Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits
This is a single-center, multiphase pilot study of 16 subjects with residual upper extremity deficits at least six months after a supratentorial ischemic or hemorrhagic stroke.
- Trial name
- NCT06288217
- Testing
- NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NeuraStasis, Inc
Safety, Efficiency
To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis
Evaluate the safety and efficacy of Hemay5394 in patients with mild to moderate atopic dermatitis
- Trial name
- NCT07877155
- Testing
- Hemay5394 group, Control group
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Hemay Pharmaceutical PTY. LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.